Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: A case report

Hiroshi Hongo, Takeo Kosaka, Eriko Aimono, Hiroshi Nishihara, Mototsugu Oya

Research output: Contribution to journalArticle

Abstract

Background: Precision medicine based on genomic analysis of germline or tumor tissue is attracting attention. However, there is no consensus on how to apply the results of genomic analysis to treatment. Case presentation: A 59-year-old man diagnosed with metastatic prostate cancer was diagnosed with castration-resistant prostate cancer. Although he was sequentially treated with enzalutamide and abiraterone, bone metastasis progression was identified by skeletal scintigraphy. Therefore, we sequentially performed docetaxel therapy followed by cabazitaxel. After the third cycle of cabazitaxel, his prostate-specific antigen level was stable at < 10 ng/mL, and no radiological progression was detected. The patient's formalin-fixed paraffin-embedded tumor biopsy specimen underwent multiple-gene testing by next-generation sequencing, which identified a FANCA homodeletion. No significant germline mutation was observed. Conclusions: We describe a case of aggressive, castration-resistant prostate cancer with FANCA homodeletion. Genomic analysis of prostate cancer tissue can be useful to determine optimal treatment of such cancers.

Original languageEnglish
Article number5
JournalDiagnostic Pathology
Volume15
Issue number1
DOIs
Publication statusPublished - 2020 Jan 13

Fingerprint

Recombinational DNA Repair
Prostatic Neoplasms
Castration
docetaxel
Genes
Neoplasms
Precision Medicine
Germ-Line Mutation
Prostate-Specific Antigen
Radionuclide Imaging
Paraffin
Formaldehyde
Therapeutics
Neoplasm Metastasis
Biopsy
Bone and Bones
cabazitaxel

Keywords

  • Castration-resistant prostate cancer
  • FANCA
  • Genomic analysis
  • Homologous recombination repair
  • Next-generation sequencing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA : A case report. / Hongo, Hiroshi; Kosaka, Takeo; Aimono, Eriko; Nishihara, Hiroshi; Oya, Mototsugu.

In: Diagnostic Pathology, Vol. 15, No. 1, 5, 13.01.2020.

Research output: Contribution to journalArticle

@article{bd638fc4d6dd415ea74943e743ac0cd8,
title = "Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: A case report",
abstract = "Background: Precision medicine based on genomic analysis of germline or tumor tissue is attracting attention. However, there is no consensus on how to apply the results of genomic analysis to treatment. Case presentation: A 59-year-old man diagnosed with metastatic prostate cancer was diagnosed with castration-resistant prostate cancer. Although he was sequentially treated with enzalutamide and abiraterone, bone metastasis progression was identified by skeletal scintigraphy. Therefore, we sequentially performed docetaxel therapy followed by cabazitaxel. After the third cycle of cabazitaxel, his prostate-specific antigen level was stable at < 10 ng/mL, and no radiological progression was detected. The patient's formalin-fixed paraffin-embedded tumor biopsy specimen underwent multiple-gene testing by next-generation sequencing, which identified a FANCA homodeletion. No significant germline mutation was observed. Conclusions: We describe a case of aggressive, castration-resistant prostate cancer with FANCA homodeletion. Genomic analysis of prostate cancer tissue can be useful to determine optimal treatment of such cancers.",
keywords = "Castration-resistant prostate cancer, FANCA, Genomic analysis, Homologous recombination repair, Next-generation sequencing",
author = "Hiroshi Hongo and Takeo Kosaka and Eriko Aimono and Hiroshi Nishihara and Mototsugu Oya",
year = "2020",
month = "1",
day = "13",
doi = "10.1186/s13000-019-0916-z",
language = "English",
volume = "15",
journal = "Diagnostic Pathology",
issn = "1746-1596",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA

T2 - A case report

AU - Hongo, Hiroshi

AU - Kosaka, Takeo

AU - Aimono, Eriko

AU - Nishihara, Hiroshi

AU - Oya, Mototsugu

PY - 2020/1/13

Y1 - 2020/1/13

N2 - Background: Precision medicine based on genomic analysis of germline or tumor tissue is attracting attention. However, there is no consensus on how to apply the results of genomic analysis to treatment. Case presentation: A 59-year-old man diagnosed with metastatic prostate cancer was diagnosed with castration-resistant prostate cancer. Although he was sequentially treated with enzalutamide and abiraterone, bone metastasis progression was identified by skeletal scintigraphy. Therefore, we sequentially performed docetaxel therapy followed by cabazitaxel. After the third cycle of cabazitaxel, his prostate-specific antigen level was stable at < 10 ng/mL, and no radiological progression was detected. The patient's formalin-fixed paraffin-embedded tumor biopsy specimen underwent multiple-gene testing by next-generation sequencing, which identified a FANCA homodeletion. No significant germline mutation was observed. Conclusions: We describe a case of aggressive, castration-resistant prostate cancer with FANCA homodeletion. Genomic analysis of prostate cancer tissue can be useful to determine optimal treatment of such cancers.

AB - Background: Precision medicine based on genomic analysis of germline or tumor tissue is attracting attention. However, there is no consensus on how to apply the results of genomic analysis to treatment. Case presentation: A 59-year-old man diagnosed with metastatic prostate cancer was diagnosed with castration-resistant prostate cancer. Although he was sequentially treated with enzalutamide and abiraterone, bone metastasis progression was identified by skeletal scintigraphy. Therefore, we sequentially performed docetaxel therapy followed by cabazitaxel. After the third cycle of cabazitaxel, his prostate-specific antigen level was stable at < 10 ng/mL, and no radiological progression was detected. The patient's formalin-fixed paraffin-embedded tumor biopsy specimen underwent multiple-gene testing by next-generation sequencing, which identified a FANCA homodeletion. No significant germline mutation was observed. Conclusions: We describe a case of aggressive, castration-resistant prostate cancer with FANCA homodeletion. Genomic analysis of prostate cancer tissue can be useful to determine optimal treatment of such cancers.

KW - Castration-resistant prostate cancer

KW - FANCA

KW - Genomic analysis

KW - Homologous recombination repair

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85077785834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077785834&partnerID=8YFLogxK

U2 - 10.1186/s13000-019-0916-z

DO - 10.1186/s13000-019-0916-z

M3 - Article

C2 - 31931827

AN - SCOPUS:85077785834

VL - 15

JO - Diagnostic Pathology

JF - Diagnostic Pathology

SN - 1746-1596

IS - 1

M1 - 5

ER -